{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:51Z","timestamp":1753892031895,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Studies have demonstrated that injectable GnRH receptor agonists further suppress cancer progression when paired with radiotherapy (RT) in patients with intermediate- to high-risk prostate adenocarcinoma. Relugolix is a newly available oral GnRH receptor antagonist that achieves swift and profound castration (total testosterone &amp;lt;20 ng\/dl) at high rates, which may shape patients\u2019 health-related quality of life. The main objective of this prospective study was to explore the effects of neoadjuvant relugolix on health-related quality of life in prostate cancer patients immediately prior to stereotactic body radiation therapy (SBRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients treated at Georgetown between January 2021 and September 2023 with neoadjuvant relugolix per an institutional protocol were included in the study (IRB 12-1775). The five-item EQ-5D-3L, a well-established tool for quantifying patient-reported health status, was administered to each patient at baseline (prior to relugolix treatment) and again 1 h before the start of SBRT. Higher EQ Visual Analog Scale (VAS) overall scores reflected better quality of life (range 0 to 100). In line with the questionnaire framework, individual elements (mobility, self-care, usual activities, pain\/discomfort, and anxiety\/depression) were rated on a three-point scale from 1 (no problems) to 3 (severe problems). McNemar\u2019s test and paired-sample t-test were performed to analyze changes pre- and post-relugolix treatment. Our investigation determined clinical significance based on minimally important difference (MID) calculated as 0.5 times the baseline standard deviation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 87 patients, average age was 71 years, 42% were non-white, and 24% were considered obese (BMI \u226530 kg\/m\u00b2). Relugolix was initiated a median of 4 months before SBRT initiation (IQR: 3.9\u20135.4), with 87% of patients reaching profound castration (&amp;lt;20 ng\/dl). The VAS overall score was notably higher at baseline (mean \u00b1 SD: 82 \u00b1 10) compared to the paired score before RT (79 \u00b1 14, p = 0.02), although this difference was not clinically significant. No statistically or clinically significant changes were observed in any of the five individual items.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of neoadjuvant relugolix prior to prostate radiation therapy had no clinically significant impact on patient-reported health-related quality of life. Moreover, no statistically significant reductions were observed in any of the five individual health-related quality of life measures. As a key direction for future research, relugolix-associated changes to healthy-related quality of life should be contrasted to those brought about by injectable GnRH agonists.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1496646","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:22Z","timestamp":1737096682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Min Jung","family":"Koh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ji","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Y.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Ayoob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Carrasquilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Leger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"B1","unstructured":"Prostate Cancer\n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.02.005","article-title":"Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant intraprostatic lesion","volume":"6","author":"Gorovets","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02389","article-title":"Dose-escalated radiation alone or in combination with short-term total androgen suppression for intermediate-risk prostate cancer: patient-reported outcomes from NRG\/Radiation Therapy Oncology Group 0815 randomized trial","volume":"41","author":"Movsas","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamaoncol.2016.3974","article-title":"Androgen deprivation therapy and dose-escalated radiotherapy for intermediate- and high-risk prostate cancer\u2014reply","volume":"3","author":"Falchook","year":"2017","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32192","article-title":"Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer","volume":"125","author":"Wassermann","year":"2019","journal-title":"Cancer"},{"key":"B11","unstructured":"EQ-5D-3L User Guide\n          \n          2018"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10719.x","article-title":"Testosterone in prostate cancer: the Bethesda consensus: role of testosterone in prostate cancer","volume":"110","author":"Djavan","year":"2012","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852844","article-title":"Patient-reported financial burden following stereotactic body radiation therapy for localized prostate cancer","volume":"12","author":"Sholklapper","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14950","article-title":"Two minimal clinically important difference (2MCID): a new twist on an old concept","volume":"98","author":"Ali","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1412786","article-title":"The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue","volume":"14","author":"Hsueh","year":"2024","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1377103","article-title":"Impact of neoadjuvant relugolix on patient-reported sexual function and bother","volume":"14","author":"Hsueh","year":"2024","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1496646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:24Z","timestamp":1737096684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1496646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":19,"alternative-id":["10.3389\/fonc.2024.1496646"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1496646","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"article-number":"1496646"}}